whatshot

TNXP   $0.2561  -11.11% Market Open

Tonix Pharmaceuticals Holding Corp
show_chart Advanced Chart of TNXP
Last Events:

2023-08-09 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: exit from the overbought zone.

2023-08-06 Trend pattern changed from нисходящий треугольник to сужающийся канал.

2023-08-06 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-05 Trend pattern changed from восходящий треугольник to нисходящий треугольник.

2023-08-02 Trend Power changed from medium strength to .

2023-07-30 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-07-30 Signal in MACD changed from bullish recovery to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: down-crossing the middle level.

2023-07-30 Signal in RSI changed from bullish recovery to bearish. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.

Current temperature: 5.51
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 3
Target Price Mean 5.8333
Mean unverified/preliminary 5.8333 / 5.8333
Target Price Low / High 2.5000 / 11.0000
Median / STD DEV 4.0000 / 4.54
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy ActivelyBuy
rsi Sell ActivelyBuy ActivelyBuy
macd None ActivelyBuy None
stoch None ActivelyBuy None
ma20 Buy ActivelyBuy ActivelyBuy
ma50 ActivelyBuy None None
ma100 ActivelyBuy Buy None
Candlestick PatternJan. 7, 2025 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US8902608475
ceo Dr. Seth Lederman M.D.
Website https://www.tonixpharma.com
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.